Targeting the epigenome for the treatment of thoracic malignancies

David S Schrump1, Dao M Nguyen

  • 1Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Room 4-3940, 10 Center Drive, MSC 1201, Bethesda, MD 20892-1201, USA. david_schrump@nih.gov

Thoracic Surgery Clinics
|January 24, 2007
PubMed

Insights

Lung cancer remains a leading cause of death. Epigenetic therapies targeting DNA methylation and histone acetylation offer new treatment strategies by remodeling chromatin. Further research will refine these approaches for better lung cancer outcomes.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Lung cancer is the primary cause of cancer mortality globally.
  • Existing diagnostic and therapeutic strategies have limitations.
  • Epigenetic dysregulation plays a key role in lung cancer development.

Purpose of the Study:

  • To explore the potential of chromatin remodeling agents in lung cancer treatment and prevention.
  • To investigate novel epigenetic mechanisms in lung cancer.
  • To identify more effective therapeutic regimens.

Main Methods:

  • Analysis of molecular responses in lung tumor tissues.
  • Investigating agents that modulate DNA methylation.
  • Studying agents that modulate histone acetylation.

Main Results:

  • Elucidation of epigenetic regulation in malignant transformation.
  • Identification of agents targeting DNA methylation and histone acetylation.
  • Potential for new therapeutic strategies via chromatin remodeling.

Conclusions:

  • Chromatin remodeling presents a promising avenue for lung cancer therapy and prevention.
  • Further analysis of molecular responses can uncover novel epigenetic targets.
  • Optimizing regimens based on epigenetic modulation may improve patient outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...